• Mashup Score: 1
    News Releases - Anthos Therapeutics - 8 month(s) ago

    Accelerating the development of life-preserving therapies for patients at high-risk of cardiovascular diseases

    Source: anthostherapeutics.com
    Categories: Expert Picks, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of CMichaelGibson
      CMichaelGibson

      PR from Anthos: DSMB stops trial of 1287 patients with atrial fibrillation at moderate-to-high risk of stroke due to an overwhelming reduction in composite of major and clinically relevant non-major bleeding in pts on #abelacimab vs #rivaroxaban, https://t.co/rfKTulnkC8